Source: International Congress 2017 – Lung fibrosis: basic science
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Chen (Chongqing, China). Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice. 902

Member's Comments

No comment yet.

Related content which might interest you: Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Effect of simvastatin on bleomycin induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Effects of drotrecogin-alpha on the bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 The effect of interferon-γ on bleomycin-induced alveolitis and pulmonary fibrosis in rats Source: Eur Respir J 2005; 26: Suppl. 49, 81s Year: 2005 The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 19: 1124-1127 Year: 2002 Effect of curcumin on inflammation in experimental pulmonary fibrosis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 20: Suppl. 38, 487s Year: 2002 Expression of TGF-β and TGFβ receptors in bleomycin-induced pulmonary fibrosis of rats Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Effects of aerosolized earthworm fibrinolytic enzyme on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 766s Year: 2006